Servier Pipeline

January 2026

SERVIER
moved by you

FOCUSED ON EXPANDING OUR PIPELINE



Data as of January 2026
* Single Pill Combination & New Formulation

Oncology – Solid tumors

Données à janvier 2026

	Cible	Indication	DPC	Phase I/II	Phase II	Phase III Potential registration	Partenaire
DAROVASERTIB	PKC	**Uveal melanoma**					IDEAYA BIOSCIENCES
IVOSIDENIB	IDH1	**Chondrosarcoma**					
IVOSIDENIB / + Durvalumab +Gemcitabine/Cisplatine		**Cholangiocarcinoma**					
VORASIDENIB / + temozolomide	IDH1/2	**Glioma**					
VORASIDENIB / + pembrolizumab		**Glioma**					
S95018	TIM3	**Non-small Cell Lung Cancer** + in association					
S95024	CD73						
S95029	NKG2A						
S95035	MAT2A	**Gastric cancer**					
S241656	RAS/RAF	**Solid tumors**					
S234821	*DSC**						

** Données Scientifiques Confidentie*

Oncology – Hematological malignancies

Données à janvier 2026

	Cible	Indication	DPC	Phase I/II	Phase II	Phase III Potential registration	Partenaire
IVOSIDENIB / + 7+3 (chemotherapy)	IDH1	**Acute Myeloid Leukemia** (new indication)					
IVOSIDENIB / Azacitidine / Venetoclax							
IVOSIDENIB							
S243249	MENIN	• **Acute Myeloid Leukemia** • **Acute Lymphoblastic Leukemia**					
S236200	*DSC**	**Hematological malignancies**					Vernalis
S247567	*DSC**						

** Données Scientifiques Confidentielles*

Neurology

As data of January 2026

	Target	Indication	DPC	Phase I/II	Phase II	Phase III Potential registration
Genetic autism spectre	BK channel	**Fragile X syndrome** is a genetic disorder caused by a mutation in the FMR1 gene, leading to a deficiency of the fragile X mental retardation protein (FMRP). This protein is crucial for normal brain development and function. The absence of FMRP disrupts synaptic plasticity, which is essential for learning and memory, resulting in cognitive impairments and behavioral challenges. Patients with Fragile X syndrome often exhibit a range of symptoms, including intellectual disability, anxiety, and social difficulties. The condition can also manifest itself through physical features such as an elongated face and enlarged ears.				

Neurology

As data of January 2026

	Target	Indication	DPC	Phase I/II	Phase II	Phase III Potential registration
Developmental and epileptic encephalopathies AntiSensOligonucleotid	KCNT1	KCNT1-related **Developmental and Epileptic Encephalopathy** (DEE) are a group of severe neurological disorders characterized by very early-onset seizures and significant developmental delays. KCNT1-DEE is caused by genetic mutations in the KCNT1 gene that disrupt normal brain development and function. The seizures are most often refractory to standard anti-epileptic medication, complicating treatment. Patients with KCNT1-DEE experience a range of symptoms, including severe cognitive impairments, motor deficits, and behavioral issues. The impact on family dynamics and overall quality of life is profound. More details about ASO technology				

Neurology

As data of January 2026

	Target	Indication	DPC	Phase I/II	Phase II	Phase III Potential registration
Developmental and epileptic encephalopathies AntiSensOligonucleotid	ND*	**Movement disorders** are a diverse group of neurological conditions characterized by abnormal movements that significantly impact daily functioning. These disorders are often due to genetic mutations, neurodegenerative processes, or environmental factors affecting the brain's motor control pathways. Common examples include sustained muscle contractions and abnormal postures, as irregular, rapid movements difficult to control. Patients with rare movement disorders often face challenges in mobility, communication, and social interactions. The unpredictability of symptoms is often associated with emotional distress and a reduced quality of life. More details about ASO technology				

**Not DIsclosed*

Cardiometabolism & Venous Diseases

As data ofJanuary 2026

	Indication	DPC	Phase I/II	Phase II	Phase III Potential registration	Filing
Ivabradine (new formulation)	**Heart Failure**					
Dapagliflozin/Bisoprolol	**Heart Failure**					
Bisoprolol/Perindopril/Indapamide/Amlodipine	**Hypertension**					
Perindopril/Indapamide SR/Amlodipine	**Hypertension**					
Gliclazide/Metformin	**T2 diabetes**					
Bisoprolol/Perindopril/Amlodipine	**Hypertension**					
Dapagliflozin/Gliclazide	**T2 diabetes**					

+5 ON GOING FEASIBILITY PROJECTS